Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromes
Authors
Keywords
-
Journal
LEUKEMIA RESEARCH
Volume 134, Issue -, Pages 107390
Publisher
Elsevier BV
Online
2023-09-20
DOI
10.1016/j.leukres.2023.107390
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors
- (2023) Maria Vieito et al. CLINICAL CANCER RESEARCH
- Management of patients with lower-risk myelodysplastic syndromes
- (2022) Andrew M. Brunner et al. Blood Cancer Journal
- Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
- (2021) Alan F. List et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
- (2021) David P. Steensma et al. LEUKEMIA
- A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies
- (2021) Manish R. Patel et al. BLOOD
- Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity
- (2021) Dirk Brehmer et al. MOLECULAR CANCER THERAPEUTICS
- Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
- (2020) Pierre Fenaux et al. NEW ENGLAND JOURNAL OF MEDICINE
- Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion–Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study
- (2020) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- 438OMETEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours
- (2019) L L Siu et al. ANNALS OF ONCOLOGY
- A Phase I/II Study to Investigate the Safety and Clinical Activity of the Protein Arginine Methyltransferase 5 Inhibitor GSK3326595 in Subjects with Myelodysplastic Syndrome and Acute Myeloid Leukemia
- (2019) Justin M. Watts et al. BLOOD
- H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers
- (2018) Michael Seiler et al. NATURE MEDICINE
- Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials
- (2018) Uwe Platzbecker et al. BLOOD
- PRMT5-Dependent Methylation of the TIP60 Coactivator RUVBL1 Is a Key Regulator of Homologous Recombination
- (2017) Thomas L. Clarke et al. MOLECULAR CELL
- Arginine Methylation: The Coming of Age
- (2017) Roméo S. Blanc et al. MOLECULAR CELL
- Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome
- (2017) Cara Lunn Shirai et al. Nature Communications
- Association between Transfusion Status and Overall Survival in Patients with Myelodysplastic Syndromes: A Systematic Literature Review and Meta-Analysis
- (2016) Sue Harnan et al. ACTA HAEMATOLOGICA
- Physiologic Expression of Sf3b1 K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation
- (2016) Esther A. Obeng et al. CANCER CELL
- New insights into transfusion-related iron toxicity: Implications for the oncologist
- (2016) John B. Porter et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis
- (2016) Daichi Inoue et al. GENES & DEVELOPMENT
- Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts
- (2016) A Mupo et al. LEUKEMIA
- Wild-Type U2AF1 Antagonizes the Splicing Program Characteristic of U2AF1-Mutant Tumors and Is Required for Cell Survival
- (2016) Dennis Liang Fei et al. PLoS Genetics
- SRSF2 Mutations Contribute to Myelodysplasia by Mutant-Specific Effects on Exon Recognition
- (2015) Eunhee Kim et al. CANCER CELL
- Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo
- (2015) Cara Lunn Shirai et al. CANCER CELL
- The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
- (2015) Nicole Stopa et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Arginine methyltransferase PRMT5 is essential for sustaining normal adult hematopoiesis
- (2015) Fan Liu et al. JOURNAL OF CLINICAL INVESTIGATION
- Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion
- (2015) A Toma et al. LEUKEMIA
- How we treat lower-risk myelodysplastic syndromes
- (2013) P. Fenaux et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started